Novel targeted pro-apoptotic agents for the treatment of prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Prostate cancer remains a significant health concern, necessitating the development of more effective therapeutic strategies.
• Apoptosis, or programmed cell death, is a critical cellular process that can be dysregulated in cancer.
• Targeting apoptotic pathways offers a promising avenue for novel cancer treatments.

Purpose of the Study:

• To review and highlight novel targeted therapies that mediate apoptosis for prostate cancer treatment.
• To explore the potential of targeting extrinsic and intrinsic apoptotic pathways.
• To categorize current and emerging apoptosis-related molecules and therapies.

Main Methods:

• Comprehensive review of peer-reviewed literature on apoptosis.
• Emphasis on apoptotic pathways and novel targeted therapies for prostate cancer.
• Categorization of therapies based on targeting apoptosis pathways, regulators, or potentiation of pro-apoptotic agents.

Main Results:

• Apoptotic pathways are broadly classified into extrinsic and intrinsic categories.
• Targeting these pathways demonstrates potential for developing novel prostate cancer agents.
• Therapies are categorized by their mechanism: direct pathway targeting, regulator targeting, or potentiation of pro-apoptotic agents.

Conclusions:

• Defining apoptosis molecules and interactions aids in developing less toxic drugs for prostate cancer.
• Ongoing clinical trials for novel pro-apoptotic agents necessitate urologist involvement.
• Familiarity with molecular pathways, benefits, and toxicities of novel agents is crucial for clinicians.